NEWS
2024-12-17 14:08
Lipum and Age Labs have been granted funding from Eurostars
Lipum AB (publ) announces that the company, together with the Norwegian company Age Labs AS, has received a grant from Eurostars. The companies will establish...
Lipum AB (publ) ("Lipum") announces its Nomination Committee for the Annual General Meeting 2025. In accordance with the decision at the Annual...
2024-11-18 10:00
Lipum Presents Promising Data on Novel Antibody SOL-116 at ACR 2024
Lipum AB (publ), a Swedish biopharmaceutical company focusing on innovative treatments for chronic inflammatory diseases, presented positive findings from...
2024-10-25 08:00
Lipum AB – interim report Q3 for the period July-September 2024
Lipum AB (publ) has published the interim report Q3 for the period July-September 2024. Below is a summary, a complete report (only in Swedish) is available...
2024-09-20 09:00
Lipum reports that the last patient has been enrolled in the ongoing phase 1 study with SOL-116
Lipum AB (publ) announces that the eighth and thus final patient with rheumatoid arthritis (RA) has been recruited and dosed with SOL-116 or placebo in...
2024-08-19 08:30
Lipum welcomes Dr. Peter Hovstadius as Chief Medical Officer
Lipum AB (publ) recruits Peter Hovstadius as the new Chief Medical Officer (CMO). Peter Hovstadius is a specialist in clinical pharmacology with a PhD...
2024-08-15 08:30
Lipum to participate in the following upcoming events and meetings
Lipum AB (publ), a clinical stage biopharmaceutical company developing the drug candidate SOL-116 focused on chronic inflammatory diseases, today announced...
2024-08-09 08:00
Lipum AB – interim report Q2 for the period January-June 2024
Lipum AB (publ) has published the interim report Q2 for the period January-June 2024. Below is a summary, a complete report (only in Swedish) is available...
2024-08-08 13:45
Lipum has received a negative preliminary report regarding the audit of the Horizon 2020 project
Lipum AB (publ) received in August 2018 a M€ 2.2 / MSEK 23 grant from the European Commission innovation program Horizon 2020. The successful project...
2024-06-18 08:30
LIPUM REPORTS FURTHER PROGRESS WHERE THE MULTIPLE DOSE PART OF THE PHASE I CLINICAL STUDY IS COMPLETED
Lipum AB (publ) announces that the multiple dose part of the phase I clinical study is completed. Eight healthy subjects have received four doses 28 days...